CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Granisetron +1 moredrug
Likely dose
Granisetron 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02230371
NCT02230371Phase 4Completed
CompareCT.gov

The Serotonin Receptor Type 3 Antagonist Granisetron as a New Treatment Approach for Patients With Chronic Myofascial Pain in the Orofacial Muscles

Karolinska Institutet·interventional·Posted Sep 3, 2014·Updated Mar 24, 2021

In Brief

A Phase 4 clinical trial evaluating Granisetron and Control (placebo) for Myofascial Pain and Temporomandibular Disorders. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The aim of this study is to to investigate if local treatment with intramuscular injections of granisetron are effective in alleviating pain in patients with chronic myofascial pain in the orofacial muscles The study hypothesis is that local administration of granisetron reduces pain and allodynia/hyperalgesia in patients with chronic myofascial pain in the orofacial muscles and that this effect of granisetron on pain is larger than the effect from placebo

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyofascial Pain, Temporomandibular Disorders
CountriesSweden
CollaboratorsFolktandvården Stockholms län AB

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 3, 2014
Enrollment StartMar 1, 2007
Primary CompletionOct 1, 2014
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7.6 yearsPosted 11.8 years ago

Interventions

Granisetrondrug

If the patient does not have any pain after the first or second injection of granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden), there will be no more injections but the patient will still come for the follow ups.

Control (placebo)drug

If the patient does not have any pain after the first or second injection of granisetron (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden), there will be no more injections but the patient will still come for the follow ups.